NutriStack
What is happening. High-dose omega-3 fatty acids (EPA/DHA) and gemfibrozil are both used to lower triglycerides and are sometimes co-prescribed. Each can modestly affect platelet function and bleeding tendency, and high-dose fish oil has been associated with a small increased risk of atrial fibrillation. There is generally no harmful pharmacokinetic interaction, and the combination is sometimes intentional for severe hypertriglyceridemia, but additive antiplatelet/bleeding effects and the AF signal warrant awareness, especially alongside anticoagulants or antiplatelet drugs.
Mechanism. Omega-3 fatty acids reduce hepatic VLDL-triglyceride synthesis (complementing the PPAR-alpha mechanism of fibrates) and produce less aggregatory eicosanoids, mildly inhibiting platelet aggregation. High-dose EPA/DHA also slightly increases atrial fibrillation risk. The combined effect is primarily additive/pharmacodynamic, not pharmacokinetic.
Recommendation. Co-use is often acceptable and sometimes intentional for severe hypertriglyceridemia, ideally under clinician guidance to track triglyceride response and avoid redundant therapy. Watch for easy bruising or bleeding, particularly if also taking aspirin, NSAIDs, or anticoagulants, and report new palpitations. Disclose fish oil use before any surgery.